Sydney M Crago, Editor, Modern Retina

OCU400 demonstrated meaningful improvement of 2-line gain (10 letters on ETDRS chart) in low-luminance visual acuity (LLVA) in treated eyes when compared to untreated fellow eyes.

City Therapeutics will develop a novel RNAi clinical candidate toward a specific disease target for intravitreal administration.

The application was refiled following a December 20, 2024, meeting between the US Food and Drug Administration (FDA) and Astellas.

The potential gene therapy candidate is being evaluated for geographic atrophy.

Let’s look back on some of the top stories on Modern Retina from 2024 as we gear up for an incredible 2025.

The trial is expected to close randomization in early December 2024.

The organization will provide resources for spreading awareness and educating patients and care givers.

Damaris Raymondi, OD, FAAO, highlighted the importance of building patient-doctor trust to learn about these practices, which can include non-traditional treatments like chamomile or manuka honey eye drops.

Sherrol Reynolds, OD, FAAO, said that multimodel imaging has been a game changer in assessing the choroidal function and structural changes in various disease conditions.

Real-world insights can clear the path to trends and strategies to meet patients’ needs.

Edmund Tsui, MD, details findings from a study that suggests that swept-source anterior segment OCT images by provide more objective ways to measure inflammation in the eye.

Michael Chaglasian, OD, details results from a study that assessed the new Monaco OCT's efficacy in glaucoma detection alongside ultra wideview imaging.

Emily Chew, MD, who won this year's Proctor Award, outlines her presentation on preparing for estimated doubling of age-related macular degeneration cases in the next 25 years at ARVO 2024.

Noel Brennan, MScOptom, PhD, overviews his ARVO 2024 presentation on reimagining the prediction of longer term efficacy numbers in data from pediatric trials evaluating myopia.

Deborah Ferrington, chief scientific officer at Doheny Eye Institute, details a session she gave on May 9 regarding mitochondria and how they change with health and in the diseased retina.

Giulia Corradetti, MD, discusses study findings that changes in microperimetry are highly localized and dependent on the OCT features.

Osamah Saeedi, MD, MS, details his ARVO 2024 presentation and the study finding's implications on monitoring and treating glaucoma.

The 2 FDA registration trials for perfluorohexyloctane resulted in scientifically significant results for improvement of mild and moderate symptoms of dry eye disease.

David A. Berntsen, OD, PhD, FAAO, talks through his 2024 ARVO presentation on the BLINK2 study and the findings on axial growth after discontinuing soft multifocal contact lens wear.

The Phase 1/2 study includes a dose-escalation phase of the study featuring 3 cohorts each one receiving either a low, medium, or high dose of OCU410.

MCO-010 demonstrated a statistically significant improvement of best-corrected visual acuity (BCVA) at week 52.

The approval marks the first new steroid on the ophthalmic market in more than 15 years.

The data indicated that patients with Alzheimer’s disease who were treated with acetylcholinesterase inhibitors had a slightly lower hazard of developing AMD compared with untreated patients.

Catch up on a few of the top stories from Modern Retina in 2023.

The study of OliX Pharmaceuticals' investigative property saw encouraging results and helped to identify suitable dosing levels for future clinical trials.

The Vision Council’s Q3 Provider Insights study shows the sentiments of eye care providers nationwide as they manage practices and patient care.

These continued studies also demonstrate a well-tolerated safety profile in a broad population of more than 1,200 patients.

Paul Hahn, MD, PhD, shared insights on research comparing the relative efficacy of pegcetacoplan versus avacincaptad pegol in patients with geographic atrophy presented at the 2023 ASRS annual meeting.

Take a look back at the first half of 2023 as we explore the role of AI in the eye care field in anticipation of the changes to come.

A recently completed non-human primate study of VGX-0111 demonstrated good tolerability, provided strong transgene expression in the targeted region of the retina, and increased production of the lipids whose decline is associated with macular degeneration.